M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Cellectis Reports Second Quarter 2025 Financial Results & Business Updates
*Cellectis to host an Investor R&D Day in New York City on October 16, 2025: Phase 1 dataset and late-stage development strategy for lasme-cel (UCART22) in r/r B-ALL to be presented
*End-of-Phase 1 meetings with FDA & EMA for lasme-cel (UCART22) in r/r B-ALL completed in July 2025; on...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search